TABLE 5.

Safety outcomes after 6 weeks of bezafibrate compared with placebo (n = 15)

	Placebo	Bezafibrate	P
AST (U/l)	34.1 ± 8.2	44.4 ± 40.2	0.3405
ALT (U/l)	30.7 ± 11.8	31.1 ± 9.6	0.9259
CK (U/l)	124 (103–143)	139 (103–194)	0.1182
Creatinine (μmol/l)	76.1 ± 10.3	86.2 ± 14.7	0.0005a
eGFR (ml/min/1.73 m2)	86.13 ± 5.85	78.4 ± 11.4	0.0021a

Data are expressed as mean ± SD or median (IQR).

^aP < 0.05.